source
- AstraZeneca halts Phase 3 lung cancer trial of volrustomig after negative resultsAstraZeneca announced on Monday that it is ending the Phase 3 study of its lung-cancer drug volrustomig after the trial failed to meet its primary efficacy endpoints. The company said the data did…
- Italian biotech sector gains traction as venture capital and tech transfer improvements boost startupsItaly has long been recognized for its high‑quality scientific research, yet converting that output into successful biotech startups has been a persistent challenge. Recent years have seen a shift…